Global Thrombin Market

Thrombin Comprehensive Study by Type (Bovine Thrombin, Human Thrombin, Recombinant Thrombin), Dosage Form (Powder Form, Solution Form), End User (Hospitals, Diagnostics Centers & Clinics, Ambulatory Surgical Centers, Academics & Research Institutes) Players and Region - Global Market Outlook to 2027

Thrombin Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Thrombin
Thrombin is a serine protease, an enzyme that, in humans, is encoded by the F2 gene. Thrombin is available in many forms as a hemostatic agent and has been purified from numerous sources and classified according to the plasma used to create it. Thrombin has high growth prospects owing to the rising prevalence of blood clotting disorders and increasing surgical activities.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Thrombin market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (United States), Johnson & Johnson Servicess, Inc. (United States), Octapharma AG (Switzerland), Baxter International Inc. (United States), Bayer AG (Germany), CSL Limited (Australia), Grifols, S.A. (Spain), GE Healthcare (United States) and Hualan Biological (China) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Thrombin market by Type (Bovine Thrombin, Human Thrombin and Recombinant Thrombin) and Region.



On the basis of geography, the market of Thrombin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Dosage Form, the sub-segment i.e. Powder Form will boost the Thrombin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Thrombin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Adoption of Smoking increasing the Prevalence of Thrombosis

Market Growth Drivers:
Growing Prevalence of Blood Clotting Disorders and Growth in the Use of Thrombin due to Adoption of Hemostats in Excessive Bleeding during Surgical Procedure

Challenges:
Ineffective in Patients who Suffer from Afibrinogenemia

Restraints:
Starigent Govermanebt Regulation

Opportunities:
Increasing Surgical Procedure due to Increasing Number of Diseases Worldwide and Growth and Advancement in Technology in the Healthcare Industry in Developing Countries

Market Leaders and their expansionary development strategies
In July 2019, Pfizer Inc. announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development, and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.
In Dec 2018, Baxter International Inc.announced the introduction of the Disposable Curved Applicator, which enhances the delivery experience of its Floseal Hemostatic Matrix product line for procedures in the otolaryngology, head, and neck surgical specialty. Floseal Matrix contains Thrombin made from human plasma.


Key Target Audience
Thrombin Suppliers/Distributors, Potential Investors, Healthcare Industry and Research and Development Organisation

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Bovine Thrombin
  • Human Thrombin
  • Recombinant Thrombin
By Dosage Form
  • Powder Form
  • Solution Form

By End User
  • Hospitals
  • Diagnostics Centers & Clinics
  • Ambulatory Surgical Centers
  • Academics & Research Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Blood Clotting Disorders
      • 3.2.2. Growth in the Use of Thrombin due to Adoption of Hemostats in Excessive Bleeding during Surgical Procedure
    • 3.3. Market Challenges
      • 3.3.1. Ineffective in Patients who Suffer from Afibrinogenemia
    • 3.4. Market Trends
      • 3.4.1. Rising Adoption of Smoking increasing the Prevalence of Thrombosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Thrombin, by Type, Dosage Form, End User and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Thrombin (Value)
      • 5.2.1. Global Thrombin by: Type (Value)
        • 5.2.1.1. Bovine Thrombin
        • 5.2.1.2. Human Thrombin
        • 5.2.1.3. Recombinant Thrombin
      • 5.2.2. Global Thrombin by: Dosage Form (Value)
        • 5.2.2.1. Powder Form
        • 5.2.2.2. Solution Form
      • 5.2.3. Global Thrombin by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Diagnostics Centers & Clinics
        • 5.2.3.3. Ambulatory Surgical Centers
        • 5.2.3.4. Academics & Research Institutes
      • 5.2.4. Global Thrombin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Thrombin (Volume)
      • 5.3.1. Global Thrombin by: Type (Volume)
        • 5.3.1.1. Bovine Thrombin
        • 5.3.1.2. Human Thrombin
        • 5.3.1.3. Recombinant Thrombin
      • 5.3.2. Global Thrombin by: Dosage Form (Volume)
        • 5.3.2.1. Powder Form
        • 5.3.2.2. Solution Form
      • 5.3.3. Global Thrombin by: End User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Diagnostics Centers & Clinics
        • 5.3.3.3. Ambulatory Surgical Centers
        • 5.3.3.4. Academics & Research Institutes
      • 5.3.4. Global Thrombin Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Thrombin (Price)
      • 5.4.1. Global Thrombin by: Type (Price)
  • 6. Thrombin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson Servicess, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Octapharma AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Baxter International Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CSL Limited (Australia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Grifols, S.A. (Spain)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GE Healthcare (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hualan Biological (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Thrombin Sale, by Type, Dosage Form, End User and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Thrombin (Value)
      • 7.2.1. Global Thrombin by: Type (Value)
        • 7.2.1.1. Bovine Thrombin
        • 7.2.1.2. Human Thrombin
        • 7.2.1.3. Recombinant Thrombin
      • 7.2.2. Global Thrombin by: Dosage Form (Value)
        • 7.2.2.1. Powder Form
        • 7.2.2.2. Solution Form
      • 7.2.3. Global Thrombin by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Diagnostics Centers & Clinics
        • 7.2.3.3. Ambulatory Surgical Centers
        • 7.2.3.4. Academics & Research Institutes
      • 7.2.4. Global Thrombin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Thrombin (Volume)
      • 7.3.1. Global Thrombin by: Type (Volume)
        • 7.3.1.1. Bovine Thrombin
        • 7.3.1.2. Human Thrombin
        • 7.3.1.3. Recombinant Thrombin
      • 7.3.2. Global Thrombin by: Dosage Form (Volume)
        • 7.3.2.1. Powder Form
        • 7.3.2.2. Solution Form
      • 7.3.3. Global Thrombin by: End User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Diagnostics Centers & Clinics
        • 7.3.3.3. Ambulatory Surgical Centers
        • 7.3.3.4. Academics & Research Institutes
      • 7.3.4. Global Thrombin Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Thrombin (Price)
      • 7.4.1. Global Thrombin by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Thrombin: by Type(USD Million)
  • Table 2. Thrombin Bovine Thrombin , by Region USD Million (2016-2021)
  • Table 3. Thrombin Human Thrombin , by Region USD Million (2016-2021)
  • Table 4. Thrombin Recombinant Thrombin , by Region USD Million (2016-2021)
  • Table 5. Thrombin: by Dosage Form(USD Million)
  • Table 6. Thrombin Powder Form , by Region USD Million (2016-2021)
  • Table 7. Thrombin Solution Form , by Region USD Million (2016-2021)
  • Table 8. Thrombin: by End User(USD Million)
  • Table 9. Thrombin Hospitals , by Region USD Million (2016-2021)
  • Table 10. Thrombin Diagnostics Centers & Clinics , by Region USD Million (2016-2021)
  • Table 11. Thrombin Ambulatory Surgical Centers , by Region USD Million (2016-2021)
  • Table 12. Thrombin Academics & Research Institutes , by Region USD Million (2016-2021)
  • Table 13. South America Thrombin, by Country USD Million (2016-2021)
  • Table 14. South America Thrombin, by Type USD Million (2016-2021)
  • Table 15. South America Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 16. South America Thrombin, by End User USD Million (2016-2021)
  • Table 17. Brazil Thrombin, by Type USD Million (2016-2021)
  • Table 18. Brazil Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 19. Brazil Thrombin, by End User USD Million (2016-2021)
  • Table 20. Argentina Thrombin, by Type USD Million (2016-2021)
  • Table 21. Argentina Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 22. Argentina Thrombin, by End User USD Million (2016-2021)
  • Table 23. Rest of South America Thrombin, by Type USD Million (2016-2021)
  • Table 24. Rest of South America Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 25. Rest of South America Thrombin, by End User USD Million (2016-2021)
  • Table 26. Asia Pacific Thrombin, by Country USD Million (2016-2021)
  • Table 27. Asia Pacific Thrombin, by Type USD Million (2016-2021)
  • Table 28. Asia Pacific Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 29. Asia Pacific Thrombin, by End User USD Million (2016-2021)
  • Table 30. China Thrombin, by Type USD Million (2016-2021)
  • Table 31. China Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 32. China Thrombin, by End User USD Million (2016-2021)
  • Table 33. Japan Thrombin, by Type USD Million (2016-2021)
  • Table 34. Japan Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 35. Japan Thrombin, by End User USD Million (2016-2021)
  • Table 36. India Thrombin, by Type USD Million (2016-2021)
  • Table 37. India Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 38. India Thrombin, by End User USD Million (2016-2021)
  • Table 39. South Korea Thrombin, by Type USD Million (2016-2021)
  • Table 40. South Korea Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 41. South Korea Thrombin, by End User USD Million (2016-2021)
  • Table 42. Taiwan Thrombin, by Type USD Million (2016-2021)
  • Table 43. Taiwan Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 44. Taiwan Thrombin, by End User USD Million (2016-2021)
  • Table 45. Australia Thrombin, by Type USD Million (2016-2021)
  • Table 46. Australia Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 47. Australia Thrombin, by End User USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Thrombin, by Type USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Thrombin, by End User USD Million (2016-2021)
  • Table 51. Europe Thrombin, by Country USD Million (2016-2021)
  • Table 52. Europe Thrombin, by Type USD Million (2016-2021)
  • Table 53. Europe Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 54. Europe Thrombin, by End User USD Million (2016-2021)
  • Table 55. Germany Thrombin, by Type USD Million (2016-2021)
  • Table 56. Germany Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 57. Germany Thrombin, by End User USD Million (2016-2021)
  • Table 58. France Thrombin, by Type USD Million (2016-2021)
  • Table 59. France Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 60. France Thrombin, by End User USD Million (2016-2021)
  • Table 61. Italy Thrombin, by Type USD Million (2016-2021)
  • Table 62. Italy Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 63. Italy Thrombin, by End User USD Million (2016-2021)
  • Table 64. United Kingdom Thrombin, by Type USD Million (2016-2021)
  • Table 65. United Kingdom Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 66. United Kingdom Thrombin, by End User USD Million (2016-2021)
  • Table 67. Netherlands Thrombin, by Type USD Million (2016-2021)
  • Table 68. Netherlands Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 69. Netherlands Thrombin, by End User USD Million (2016-2021)
  • Table 70. Rest of Europe Thrombin, by Type USD Million (2016-2021)
  • Table 71. Rest of Europe Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 72. Rest of Europe Thrombin, by End User USD Million (2016-2021)
  • Table 73. MEA Thrombin, by Country USD Million (2016-2021)
  • Table 74. MEA Thrombin, by Type USD Million (2016-2021)
  • Table 75. MEA Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 76. MEA Thrombin, by End User USD Million (2016-2021)
  • Table 77. Middle East Thrombin, by Type USD Million (2016-2021)
  • Table 78. Middle East Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 79. Middle East Thrombin, by End User USD Million (2016-2021)
  • Table 80. Africa Thrombin, by Type USD Million (2016-2021)
  • Table 81. Africa Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 82. Africa Thrombin, by End User USD Million (2016-2021)
  • Table 83. North America Thrombin, by Country USD Million (2016-2021)
  • Table 84. North America Thrombin, by Type USD Million (2016-2021)
  • Table 85. North America Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 86. North America Thrombin, by End User USD Million (2016-2021)
  • Table 87. United States Thrombin, by Type USD Million (2016-2021)
  • Table 88. United States Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 89. United States Thrombin, by End User USD Million (2016-2021)
  • Table 90. Canada Thrombin, by Type USD Million (2016-2021)
  • Table 91. Canada Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 92. Canada Thrombin, by End User USD Million (2016-2021)
  • Table 93. Mexico Thrombin, by Type USD Million (2016-2021)
  • Table 94. Mexico Thrombin, by Dosage Form USD Million (2016-2021)
  • Table 95. Mexico Thrombin, by End User USD Million (2016-2021)
  • Table 96. Thrombin Sales: by Type(K Units)
  • Table 97. Thrombin Sales Bovine Thrombin , by Region K Units (2016-2021)
  • Table 98. Thrombin Sales Human Thrombin , by Region K Units (2016-2021)
  • Table 99. Thrombin Sales Recombinant Thrombin , by Region K Units (2016-2021)
  • Table 100. Thrombin Sales: by Dosage Form(K Units)
  • Table 101. Thrombin Sales Powder Form , by Region K Units (2016-2021)
  • Table 102. Thrombin Sales Solution Form , by Region K Units (2016-2021)
  • Table 103. Thrombin Sales: by End User(K Units)
  • Table 104. Thrombin Sales Hospitals , by Region K Units (2016-2021)
  • Table 105. Thrombin Sales Diagnostics Centers & Clinics , by Region K Units (2016-2021)
  • Table 106. Thrombin Sales Ambulatory Surgical Centers , by Region K Units (2016-2021)
  • Table 107. Thrombin Sales Academics & Research Institutes , by Region K Units (2016-2021)
  • Table 108. South America Thrombin Sales, by Country K Units (2016-2021)
  • Table 109. South America Thrombin Sales, by Type K Units (2016-2021)
  • Table 110. South America Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 111. South America Thrombin Sales, by End User K Units (2016-2021)
  • Table 112. Brazil Thrombin Sales, by Type K Units (2016-2021)
  • Table 113. Brazil Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 114. Brazil Thrombin Sales, by End User K Units (2016-2021)
  • Table 115. Argentina Thrombin Sales, by Type K Units (2016-2021)
  • Table 116. Argentina Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 117. Argentina Thrombin Sales, by End User K Units (2016-2021)
  • Table 118. Rest of South America Thrombin Sales, by Type K Units (2016-2021)
  • Table 119. Rest of South America Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 120. Rest of South America Thrombin Sales, by End User K Units (2016-2021)
  • Table 121. Asia Pacific Thrombin Sales, by Country K Units (2016-2021)
  • Table 122. Asia Pacific Thrombin Sales, by Type K Units (2016-2021)
  • Table 123. Asia Pacific Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 124. Asia Pacific Thrombin Sales, by End User K Units (2016-2021)
  • Table 125. China Thrombin Sales, by Type K Units (2016-2021)
  • Table 126. China Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 127. China Thrombin Sales, by End User K Units (2016-2021)
  • Table 128. Japan Thrombin Sales, by Type K Units (2016-2021)
  • Table 129. Japan Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 130. Japan Thrombin Sales, by End User K Units (2016-2021)
  • Table 131. India Thrombin Sales, by Type K Units (2016-2021)
  • Table 132. India Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 133. India Thrombin Sales, by End User K Units (2016-2021)
  • Table 134. South Korea Thrombin Sales, by Type K Units (2016-2021)
  • Table 135. South Korea Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 136. South Korea Thrombin Sales, by End User K Units (2016-2021)
  • Table 137. Taiwan Thrombin Sales, by Type K Units (2016-2021)
  • Table 138. Taiwan Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 139. Taiwan Thrombin Sales, by End User K Units (2016-2021)
  • Table 140. Australia Thrombin Sales, by Type K Units (2016-2021)
  • Table 141. Australia Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 142. Australia Thrombin Sales, by End User K Units (2016-2021)
  • Table 143. Rest of Asia-Pacific Thrombin Sales, by Type K Units (2016-2021)
  • Table 144. Rest of Asia-Pacific Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 145. Rest of Asia-Pacific Thrombin Sales, by End User K Units (2016-2021)
  • Table 146. Europe Thrombin Sales, by Country K Units (2016-2021)
  • Table 147. Europe Thrombin Sales, by Type K Units (2016-2021)
  • Table 148. Europe Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 149. Europe Thrombin Sales, by End User K Units (2016-2021)
  • Table 150. Germany Thrombin Sales, by Type K Units (2016-2021)
  • Table 151. Germany Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 152. Germany Thrombin Sales, by End User K Units (2016-2021)
  • Table 153. France Thrombin Sales, by Type K Units (2016-2021)
  • Table 154. France Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 155. France Thrombin Sales, by End User K Units (2016-2021)
  • Table 156. Italy Thrombin Sales, by Type K Units (2016-2021)
  • Table 157. Italy Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 158. Italy Thrombin Sales, by End User K Units (2016-2021)
  • Table 159. United Kingdom Thrombin Sales, by Type K Units (2016-2021)
  • Table 160. United Kingdom Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 161. United Kingdom Thrombin Sales, by End User K Units (2016-2021)
  • Table 162. Netherlands Thrombin Sales, by Type K Units (2016-2021)
  • Table 163. Netherlands Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 164. Netherlands Thrombin Sales, by End User K Units (2016-2021)
  • Table 165. Rest of Europe Thrombin Sales, by Type K Units (2016-2021)
  • Table 166. Rest of Europe Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 167. Rest of Europe Thrombin Sales, by End User K Units (2016-2021)
  • Table 168. MEA Thrombin Sales, by Country K Units (2016-2021)
  • Table 169. MEA Thrombin Sales, by Type K Units (2016-2021)
  • Table 170. MEA Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 171. MEA Thrombin Sales, by End User K Units (2016-2021)
  • Table 172. Middle East Thrombin Sales, by Type K Units (2016-2021)
  • Table 173. Middle East Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 174. Middle East Thrombin Sales, by End User K Units (2016-2021)
  • Table 175. Africa Thrombin Sales, by Type K Units (2016-2021)
  • Table 176. Africa Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 177. Africa Thrombin Sales, by End User K Units (2016-2021)
  • Table 178. North America Thrombin Sales, by Country K Units (2016-2021)
  • Table 179. North America Thrombin Sales, by Type K Units (2016-2021)
  • Table 180. North America Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 181. North America Thrombin Sales, by End User K Units (2016-2021)
  • Table 182. United States Thrombin Sales, by Type K Units (2016-2021)
  • Table 183. United States Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 184. United States Thrombin Sales, by End User K Units (2016-2021)
  • Table 185. Canada Thrombin Sales, by Type K Units (2016-2021)
  • Table 186. Canada Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 187. Canada Thrombin Sales, by End User K Units (2016-2021)
  • Table 188. Mexico Thrombin Sales, by Type K Units (2016-2021)
  • Table 189. Mexico Thrombin Sales, by Dosage Form K Units (2016-2021)
  • Table 190. Mexico Thrombin Sales, by End User K Units (2016-2021)
  • Table 191. Thrombin: by Type(USD/Units)
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Thrombin: by Type(USD Million)
  • Table 202. Thrombin Bovine Thrombin , by Region USD Million (2022-2027)
  • Table 203. Thrombin Human Thrombin , by Region USD Million (2022-2027)
  • Table 204. Thrombin Recombinant Thrombin , by Region USD Million (2022-2027)
  • Table 205. Thrombin: by Dosage Form(USD Million)
  • Table 206. Thrombin Powder Form , by Region USD Million (2022-2027)
  • Table 207. Thrombin Solution Form , by Region USD Million (2022-2027)
  • Table 208. Thrombin: by End User(USD Million)
  • Table 209. Thrombin Hospitals , by Region USD Million (2022-2027)
  • Table 210. Thrombin Diagnostics Centers & Clinics , by Region USD Million (2022-2027)
  • Table 211. Thrombin Ambulatory Surgical Centers , by Region USD Million (2022-2027)
  • Table 212. Thrombin Academics & Research Institutes , by Region USD Million (2022-2027)
  • Table 213. South America Thrombin, by Country USD Million (2022-2027)
  • Table 214. South America Thrombin, by Type USD Million (2022-2027)
  • Table 215. South America Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 216. South America Thrombin, by End User USD Million (2022-2027)
  • Table 217. Brazil Thrombin, by Type USD Million (2022-2027)
  • Table 218. Brazil Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 219. Brazil Thrombin, by End User USD Million (2022-2027)
  • Table 220. Argentina Thrombin, by Type USD Million (2022-2027)
  • Table 221. Argentina Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 222. Argentina Thrombin, by End User USD Million (2022-2027)
  • Table 223. Rest of South America Thrombin, by Type USD Million (2022-2027)
  • Table 224. Rest of South America Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 225. Rest of South America Thrombin, by End User USD Million (2022-2027)
  • Table 226. Asia Pacific Thrombin, by Country USD Million (2022-2027)
  • Table 227. Asia Pacific Thrombin, by Type USD Million (2022-2027)
  • Table 228. Asia Pacific Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 229. Asia Pacific Thrombin, by End User USD Million (2022-2027)
  • Table 230. China Thrombin, by Type USD Million (2022-2027)
  • Table 231. China Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 232. China Thrombin, by End User USD Million (2022-2027)
  • Table 233. Japan Thrombin, by Type USD Million (2022-2027)
  • Table 234. Japan Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 235. Japan Thrombin, by End User USD Million (2022-2027)
  • Table 236. India Thrombin, by Type USD Million (2022-2027)
  • Table 237. India Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 238. India Thrombin, by End User USD Million (2022-2027)
  • Table 239. South Korea Thrombin, by Type USD Million (2022-2027)
  • Table 240. South Korea Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 241. South Korea Thrombin, by End User USD Million (2022-2027)
  • Table 242. Taiwan Thrombin, by Type USD Million (2022-2027)
  • Table 243. Taiwan Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 244. Taiwan Thrombin, by End User USD Million (2022-2027)
  • Table 245. Australia Thrombin, by Type USD Million (2022-2027)
  • Table 246. Australia Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 247. Australia Thrombin, by End User USD Million (2022-2027)
  • Table 248. Rest of Asia-Pacific Thrombin, by Type USD Million (2022-2027)
  • Table 249. Rest of Asia-Pacific Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 250. Rest of Asia-Pacific Thrombin, by End User USD Million (2022-2027)
  • Table 251. Europe Thrombin, by Country USD Million (2022-2027)
  • Table 252. Europe Thrombin, by Type USD Million (2022-2027)
  • Table 253. Europe Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 254. Europe Thrombin, by End User USD Million (2022-2027)
  • Table 255. Germany Thrombin, by Type USD Million (2022-2027)
  • Table 256. Germany Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 257. Germany Thrombin, by End User USD Million (2022-2027)
  • Table 258. France Thrombin, by Type USD Million (2022-2027)
  • Table 259. France Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 260. France Thrombin, by End User USD Million (2022-2027)
  • Table 261. Italy Thrombin, by Type USD Million (2022-2027)
  • Table 262. Italy Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 263. Italy Thrombin, by End User USD Million (2022-2027)
  • Table 264. United Kingdom Thrombin, by Type USD Million (2022-2027)
  • Table 265. United Kingdom Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 266. United Kingdom Thrombin, by End User USD Million (2022-2027)
  • Table 267. Netherlands Thrombin, by Type USD Million (2022-2027)
  • Table 268. Netherlands Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 269. Netherlands Thrombin, by End User USD Million (2022-2027)
  • Table 270. Rest of Europe Thrombin, by Type USD Million (2022-2027)
  • Table 271. Rest of Europe Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 272. Rest of Europe Thrombin, by End User USD Million (2022-2027)
  • Table 273. MEA Thrombin, by Country USD Million (2022-2027)
  • Table 274. MEA Thrombin, by Type USD Million (2022-2027)
  • Table 275. MEA Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 276. MEA Thrombin, by End User USD Million (2022-2027)
  • Table 277. Middle East Thrombin, by Type USD Million (2022-2027)
  • Table 278. Middle East Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 279. Middle East Thrombin, by End User USD Million (2022-2027)
  • Table 280. Africa Thrombin, by Type USD Million (2022-2027)
  • Table 281. Africa Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 282. Africa Thrombin, by End User USD Million (2022-2027)
  • Table 283. North America Thrombin, by Country USD Million (2022-2027)
  • Table 284. North America Thrombin, by Type USD Million (2022-2027)
  • Table 285. North America Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 286. North America Thrombin, by End User USD Million (2022-2027)
  • Table 287. United States Thrombin, by Type USD Million (2022-2027)
  • Table 288. United States Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 289. United States Thrombin, by End User USD Million (2022-2027)
  • Table 290. Canada Thrombin, by Type USD Million (2022-2027)
  • Table 291. Canada Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 292. Canada Thrombin, by End User USD Million (2022-2027)
  • Table 293. Mexico Thrombin, by Type USD Million (2022-2027)
  • Table 294. Mexico Thrombin, by Dosage Form USD Million (2022-2027)
  • Table 295. Mexico Thrombin, by End User USD Million (2022-2027)
  • Table 296. Thrombin Sales: by Type(K Units)
  • Table 297. Thrombin Sales Bovine Thrombin , by Region K Units (2022-2027)
  • Table 298. Thrombin Sales Human Thrombin , by Region K Units (2022-2027)
  • Table 299. Thrombin Sales Recombinant Thrombin , by Region K Units (2022-2027)
  • Table 300. Thrombin Sales: by Dosage Form(K Units)
  • Table 301. Thrombin Sales Powder Form , by Region K Units (2022-2027)
  • Table 302. Thrombin Sales Solution Form , by Region K Units (2022-2027)
  • Table 303. Thrombin Sales: by End User(K Units)
  • Table 304. Thrombin Sales Hospitals , by Region K Units (2022-2027)
  • Table 305. Thrombin Sales Diagnostics Centers & Clinics , by Region K Units (2022-2027)
  • Table 306. Thrombin Sales Ambulatory Surgical Centers , by Region K Units (2022-2027)
  • Table 307. Thrombin Sales Academics & Research Institutes , by Region K Units (2022-2027)
  • Table 308. South America Thrombin Sales, by Country K Units (2022-2027)
  • Table 309. South America Thrombin Sales, by Type K Units (2022-2027)
  • Table 310. South America Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 311. South America Thrombin Sales, by End User K Units (2022-2027)
  • Table 312. Brazil Thrombin Sales, by Type K Units (2022-2027)
  • Table 313. Brazil Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 314. Brazil Thrombin Sales, by End User K Units (2022-2027)
  • Table 315. Argentina Thrombin Sales, by Type K Units (2022-2027)
  • Table 316. Argentina Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 317. Argentina Thrombin Sales, by End User K Units (2022-2027)
  • Table 318. Rest of South America Thrombin Sales, by Type K Units (2022-2027)
  • Table 319. Rest of South America Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 320. Rest of South America Thrombin Sales, by End User K Units (2022-2027)
  • Table 321. Asia Pacific Thrombin Sales, by Country K Units (2022-2027)
  • Table 322. Asia Pacific Thrombin Sales, by Type K Units (2022-2027)
  • Table 323. Asia Pacific Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 324. Asia Pacific Thrombin Sales, by End User K Units (2022-2027)
  • Table 325. China Thrombin Sales, by Type K Units (2022-2027)
  • Table 326. China Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 327. China Thrombin Sales, by End User K Units (2022-2027)
  • Table 328. Japan Thrombin Sales, by Type K Units (2022-2027)
  • Table 329. Japan Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 330. Japan Thrombin Sales, by End User K Units (2022-2027)
  • Table 331. India Thrombin Sales, by Type K Units (2022-2027)
  • Table 332. India Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 333. India Thrombin Sales, by End User K Units (2022-2027)
  • Table 334. South Korea Thrombin Sales, by Type K Units (2022-2027)
  • Table 335. South Korea Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 336. South Korea Thrombin Sales, by End User K Units (2022-2027)
  • Table 337. Taiwan Thrombin Sales, by Type K Units (2022-2027)
  • Table 338. Taiwan Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 339. Taiwan Thrombin Sales, by End User K Units (2022-2027)
  • Table 340. Australia Thrombin Sales, by Type K Units (2022-2027)
  • Table 341. Australia Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 342. Australia Thrombin Sales, by End User K Units (2022-2027)
  • Table 343. Rest of Asia-Pacific Thrombin Sales, by Type K Units (2022-2027)
  • Table 344. Rest of Asia-Pacific Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 345. Rest of Asia-Pacific Thrombin Sales, by End User K Units (2022-2027)
  • Table 346. Europe Thrombin Sales, by Country K Units (2022-2027)
  • Table 347. Europe Thrombin Sales, by Type K Units (2022-2027)
  • Table 348. Europe Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 349. Europe Thrombin Sales, by End User K Units (2022-2027)
  • Table 350. Germany Thrombin Sales, by Type K Units (2022-2027)
  • Table 351. Germany Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 352. Germany Thrombin Sales, by End User K Units (2022-2027)
  • Table 353. France Thrombin Sales, by Type K Units (2022-2027)
  • Table 354. France Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 355. France Thrombin Sales, by End User K Units (2022-2027)
  • Table 356. Italy Thrombin Sales, by Type K Units (2022-2027)
  • Table 357. Italy Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 358. Italy Thrombin Sales, by End User K Units (2022-2027)
  • Table 359. United Kingdom Thrombin Sales, by Type K Units (2022-2027)
  • Table 360. United Kingdom Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 361. United Kingdom Thrombin Sales, by End User K Units (2022-2027)
  • Table 362. Netherlands Thrombin Sales, by Type K Units (2022-2027)
  • Table 363. Netherlands Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 364. Netherlands Thrombin Sales, by End User K Units (2022-2027)
  • Table 365. Rest of Europe Thrombin Sales, by Type K Units (2022-2027)
  • Table 366. Rest of Europe Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 367. Rest of Europe Thrombin Sales, by End User K Units (2022-2027)
  • Table 368. MEA Thrombin Sales, by Country K Units (2022-2027)
  • Table 369. MEA Thrombin Sales, by Type K Units (2022-2027)
  • Table 370. MEA Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 371. MEA Thrombin Sales, by End User K Units (2022-2027)
  • Table 372. Middle East Thrombin Sales, by Type K Units (2022-2027)
  • Table 373. Middle East Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 374. Middle East Thrombin Sales, by End User K Units (2022-2027)
  • Table 375. Africa Thrombin Sales, by Type K Units (2022-2027)
  • Table 376. Africa Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 377. Africa Thrombin Sales, by End User K Units (2022-2027)
  • Table 378. North America Thrombin Sales, by Country K Units (2022-2027)
  • Table 379. North America Thrombin Sales, by Type K Units (2022-2027)
  • Table 380. North America Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 381. North America Thrombin Sales, by End User K Units (2022-2027)
  • Table 382. United States Thrombin Sales, by Type K Units (2022-2027)
  • Table 383. United States Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 384. United States Thrombin Sales, by End User K Units (2022-2027)
  • Table 385. Canada Thrombin Sales, by Type K Units (2022-2027)
  • Table 386. Canada Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 387. Canada Thrombin Sales, by End User K Units (2022-2027)
  • Table 388. Mexico Thrombin Sales, by Type K Units (2022-2027)
  • Table 389. Mexico Thrombin Sales, by Dosage Form K Units (2022-2027)
  • Table 390. Mexico Thrombin Sales, by End User K Units (2022-2027)
  • Table 391. Thrombin: by Type(USD/Units)
  • Table 392. Research Programs/Design for This Report
  • Table 393. Key Data Information from Secondary Sources
  • Table 394. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Thrombin: by Type USD Million (2016-2021)
  • Figure 5. Global Thrombin: by Dosage Form USD Million (2016-2021)
  • Figure 6. Global Thrombin: by End User USD Million (2016-2021)
  • Figure 7. South America Thrombin Share (%), by Country
  • Figure 8. Asia Pacific Thrombin Share (%), by Country
  • Figure 9. Europe Thrombin Share (%), by Country
  • Figure 10. MEA Thrombin Share (%), by Country
  • Figure 11. North America Thrombin Share (%), by Country
  • Figure 12. Global Thrombin: by Type K Units (2016-2021)
  • Figure 13. Global Thrombin: by Dosage Form K Units (2016-2021)
  • Figure 14. Global Thrombin: by End User K Units (2016-2021)
  • Figure 15. South America Thrombin Share (%), by Country
  • Figure 16. Asia Pacific Thrombin Share (%), by Country
  • Figure 17. Europe Thrombin Share (%), by Country
  • Figure 18. MEA Thrombin Share (%), by Country
  • Figure 19. North America Thrombin Share (%), by Country
  • Figure 20. Global Thrombin: by Type USD/Units (2016-2021)
  • Figure 21. Global Thrombin share by Players 2021 (%)
  • Figure 22. Global Thrombin share by Players (Top 3) 2021(%)
  • Figure 23. Global Thrombin share by Players (Top 5) 2021(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer (United States) Revenue: by Geography 2021
  • Figure 27. Johnson & Johnson Servicess, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson Servicess, Inc. (United States) Revenue: by Geography 2021
  • Figure 29. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Octapharma AG (Switzerland) Revenue: by Geography 2021
  • Figure 31. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Baxter International Inc. (United States) Revenue: by Geography 2021
  • Figure 33. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 35. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 36. CSL Limited (Australia) Revenue: by Geography 2021
  • Figure 37. Grifols, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 38. Grifols, S.A. (Spain) Revenue: by Geography 2021
  • Figure 39. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 40. GE Healthcare (United States) Revenue: by Geography 2021
  • Figure 41. Hualan Biological (China) Revenue, Net Income and Gross profit
  • Figure 42. Hualan Biological (China) Revenue: by Geography 2021
  • Figure 43. Global Thrombin: by Type USD Million (2022-2027)
  • Figure 44. Global Thrombin: by Dosage Form USD Million (2022-2027)
  • Figure 45. Global Thrombin: by End User USD Million (2022-2027)
  • Figure 46. South America Thrombin Share (%), by Country
  • Figure 47. Asia Pacific Thrombin Share (%), by Country
  • Figure 48. Europe Thrombin Share (%), by Country
  • Figure 49. MEA Thrombin Share (%), by Country
  • Figure 50. North America Thrombin Share (%), by Country
  • Figure 51. Global Thrombin: by Type K Units (2022-2027)
  • Figure 52. Global Thrombin: by Dosage Form K Units (2022-2027)
  • Figure 53. Global Thrombin: by End User K Units (2022-2027)
  • Figure 54. South America Thrombin Share (%), by Country
  • Figure 55. Asia Pacific Thrombin Share (%), by Country
  • Figure 56. Europe Thrombin Share (%), by Country
  • Figure 57. MEA Thrombin Share (%), by Country
  • Figure 58. North America Thrombin Share (%), by Country
  • Figure 59. Global Thrombin: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Johnson & Johnson Servicess, Inc. (United States)
  • Octapharma AG (Switzerland)
  • Baxter International Inc. (United States)
  • Bayer AG (Germany)
  • CSL Limited (Australia)
  • Grifols, S.A. (Spain)
  • GE Healthcare (United States)
  • Hualan Biological (China)
Select User Access Type

Key Highlights of Report


Apr 2024 228 Pages 67 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Thrombin Market Quantitative research analysis
Global Thrombin Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (United States), Johnson & Johnson Servicess, Inc. (United States), Octapharma AG (Switzerland), Baxter International Inc. (United States), Bayer AG (Germany), CSL Limited (Australia), Grifols, S.A. (Spain), GE Healthcare (United States) and Hualan Biological (China) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Adoption of Smoking increasing the Prevalence of Thrombosis" is seen as one of major influencing trends for Thrombin Market during projected period 2021-2027.
The Thrombin market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Thrombin Market Report?

Have a Query? Click Here

Other Related Reports

Heavy Metal Poisoning Drugs Comprehensive Study by Type (ALN-TMP, Deferasirox, Deferoxamine Mesylate, Emeramide, Others), Application (Arsenic Toxicity, Chromium Toxicity, Copper Toxicity, Lead Toxic...
$ 3750
Pharmaceutical Robots Comprehensive Study by Type (Traditional Robots {Articulated, SCARA, Delta Parallel and Cartesian}, Collaborative Robots), Application (Picking and Packaging, Inspection of Drug...
$ 3450
Hypertension Drugs Comprehensive Study by Type (Systemic Hypertension Drugs, Pulmonary Hypertension Drugs), Application (Hospital Use, Clinic Use, Others), Distribution Channel (Retail Pharmacies, Ho...
$ 3750
High Blood Pressure Drugs Comprehensive Study by Type (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Vasodilators, Alpha Blockers, Re...
$ 3750
Nanoemulsion Comprehensive Study by Type (Nanocapsule, Lipid Nanocapsule, Nanosphere, Others), Application (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Antimicrobial, Anticancer, Anaesthetics, Ant...
$ 3750
Biotin Comprehensive Study by Type (Tablets, Capsules ( Soft gel capsules, Hard gel capsules), Lotions, Serums, Others), Application (Food, Pharma & Cosmetics, Animal Feed), Biotin Type (1% D-Biotin ...
$ 3450